What question did this study set out to answer?

The aim is to evaluate the effectiveness of a four-compound nutraceutical formulation for cholesterol management.

April 5, 2026Open Access

Multi-Pathway Cholesterol Management with Policosanol, Monacolin K, Auricularia auricula-judae, and Pleurotus ostreatus: Evidence Review of AURI 25 by Zenius Labs™

Key Points

The aim is to evaluate the effectiveness of a four-compound nutraceutical formulation for cholesterol management.
Review of preclinical and clinical evidence on AURI 25's components
Analysis of cholesterol-lowering mechanisms including ABCA1/ABCG1 promotion and SREBP-1c suppression
Synthesis of over 100 primary studies evaluating efficacy and safety
Auricularia auricula-judae reduced total cholesterol by up to 20.3%
Monacolin K provided clinically validated LDL reductions of 14–17%
The formulation targets multiple pathways for comprehensive cholesterol management

Abstract

This evidence review evaluates the preclinical and clinical evidence supporting a four-compound nutraceutical formulation (AURI 25, Zenius Labs™) combining Auricularia auricula-judae polysaccharides, Pleurotus ostreatus polysaccharides, policosanol, and monacolin K from red yeast rice for multi-pathway cholesterol and cardiovascular risk management. Auricularia auricula-judae polysaccharides consistently reduce total cholesterol (by up to 20.3%), LDL-cholesterol, and triglycerides in preclinical models through ABCA1/ABCG1 cholesterol efflux promotion, SREBP-1c hepatic lipogenic suppression, enhanced lipoprotein lipase activity, and insulin sensitisation that attenuates VLDL overproduction. Pleurotus ostreatus provides naturally occurring lovastatin — chemically identical to prescription statins — alongside β-glucan-mediated bile acid sequestration. Monacolin K at 2.99 mg delivers clinically validated LDL-cholesterol reductions of 14–17% across dedicated randomised controlled trials. The review synthesises over 100 primary studies across 198 references, evaluating mechanisms, safety, pharmacokinetics, and comparative positioning. The four-pathway architecture recapitulates the combination therapy principle validated by the IMPROVE-IT trial (18,144 patients) and addresses cholesterol synthesis, absorption, oxidation, and vascular risk simultaneously. Full product specifications: BioLabs.lt | Manufacturer: Zenius Labs™ | Evidence platform: Medix.lt

Multi-Pathway Cholesterol Management with Policosanol, Monacolin K, Auricularia auricula-judae, and Pleurotus ostreatus: Evidence Review of AURI 25 by Zenius Labs™

Key Points

Abstract

Cite This Study